You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 290 No. 11, September 17, 2003 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Viral Infections
 •Endocrine Diseases
 •Diabetes Mellitus
 •Gastroenterology
 •Liver/ Biliary Tract/ Pancreatic Diseases
 •Infectious Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Clinical Aspects of Chronic Hepatitis C Infection

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Flamm1 briefly addressed the question of whether medication should be discontinued early in patients with HCV who do not respond early to treatment. Early virologic response, defined as a minimum 2 log decrease in viral load during the first 12 weeks of treatment, is predictive of sustained virologic response.2 Flamm recommended stopping treatment if quantitative HCV-RNA titers do not decline by more than 2 logs by week 12 of therapy, in patients infected by either genotype 1, 2, or 3. Patients with genotype 1 who fail to achieve an early response at week 12 of treatment have only a small chance of achieving a sustained response even if therapy is continued for a full year.3 However, patients infected by genotype 2 or 3 have a high probability of a sustained response.3 Thus, viral-RNA quantification at 12 weeks does not seem warranted in either of these situations. . . . [Full Text of this Article]

Hakan Leblebicioglu, MD
Department of Infectious Diseases and Clinical Microbiology
Ondokuz Mayis University Medical School
Samsun, Turkey



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Clinical Aspects of Chronic Hepatitis C Infection
Ajit Singh Kashyap, Kuldeep Parkash Anand, and Surekha Kashyap
JAMA. 2003;290(11):1452.
EXTRACT | FULL TEXT  

Clinical Aspects of Chronic Hepatitis C Infection
Ami Schattner and Hilla Knobler
JAMA. 2003;290(11):1453.
EXTRACT | FULL TEXT  

Clinical Aspects of Chronic Hepatitis C Infection—Reply
Steven L. Flamm
JAMA. 2003;290(11):1453-1454.
EXTRACT | FULL TEXT  

Chronic Hepatitis C Virus Infection
Steven L. Flamm
JAMA. 2003;289(18):2413-2417.
EXTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.